Immunohistochemical Expression of COX2 in Urothelial Carcinoma of the urinary bladder

Shayan Khattab  Omer; Jalal Ali  Jalal; Zheen  Othman

doi:10.56056/amj.2024.291

Authors

Shayan Khattab Omer M.B.Ch.B,SHO of Histopathology in Rizgary Teaching Hospital, trainee of KHCMS, Erbil city.
Jalal Ali Jalal M.B.Ch.B, MSc, FIBMS, Consultant Histopathologist in Rizgary Teaching Hospital, Professor in Hawler Medical University- College of Medicine, Erbil
Zheen Othman M.B.Ch.B, KHCMS, Consultant histopathologist at Hawler Medical University- College of Medicine, Erbil

DOI:

https://doi.org/10.56056/amj.2024.291

Keywords:

COX2, Immunohistochemistry, Urothelial carcinoma

Abstract

Background and objectives: Urothelial carcinoma of urinary bladder constitutes 90% of bladder cancer cases. Cyclo-oxygenase 2 as an immune-histochemical marker, is not expressed in normal tissues, while it is expressed in some cancers including urothelial carcinoma. The purpose of this study is detecting the frequency of expression of Cyclo-oxygenase 2 in urinary bladder’s urothelial carcinoma in association with certain clinicopathological variables.

Methods: A retrospective study was done on seventy-nine cases (fixed with formalin and embedded in paraffin) of urothelial carcinoma which were chosen haphazardly from a private laboratory in Erbil city over two years (between October 2019 to October 2021). In the present study, Cyclo-oxygenase 2 expression was assessed on the urothelial carcinoma slides.

Results: Cyclo-oxygenase 2 was positive in 45.6% of the cases. It was positive in 80% of non-papillary tumors, while it was less expressed (40.6%) in papillary tumors, which means that significant correlation was seen between Cyclo-oxygenase 2 positivity and tumor pattern (papillary vs non-papillary) (p = 0.037). In this study, no important association was found between Cyclo-oxygenase 2 expression and other clinicopathologic features like age (p=0.236), gender (p=517), tumor grade (p=0.106), lymphovascular invasion (p=0.696) and T stage (p=0.061).

Conclusion: In this study Cyclo-oxygenase 2 was expressed in less than half of our urothelial tumor samples. A strong association was found between Cyclo-oxygenase 2 positivity and tumor pattern (papillary and non-papillary), but no important association was found between Cyclo-oxygenase 2 positivity and other variables such as age, gender, tumor grade, lymphovascular invasion and tumor stage.

Downloads

Download data is not yet available.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394-424.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209-49.

Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020;8(1):15.

Hussain AM, Lafta RK. Cancer Trends in Iraq 2000–2016. Oman Med J. 2021;36(1): e219.

Khoshnaw N, Mohammed HA, Abdullah DA. Patterns of cancer in Kurdistan-results of eight years cancer registration in Sulaymaniyah Province-Kurdistan-Iraq. Asian Pac J Cancer Prev. 2016;16(18):8525-31.

Shih C, Hotaling JM, Wright JL, White E, editors. Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and Lifestyle (VITAL) study. Urol Oncol: Semin Orig. 2013;31(8): 1689-95).

Allaj V, Guo C, Nie D. Non-steroid anti-inflammatory drugs, prostaglandins, and cancer. Cell Biosci. 2013;3(1):1-13.

Vogel LK, Sæbø M, Høyer H, Kopp TI, Vogel U, Godiksen S, et al. Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis. PloS one. 2014;9(8): e105254.

Thanan R, Murata M, Ma N, Hammam O, Wishahi M, El Leithy T, et al. nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. Mediators Inflamm. 2012;2012.

Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517(7533):209-13.

Rudnick JA, Arendt LM, Klebba I, Hinds JW, Iyer V, Gupta PB, et al. Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells. PloS one. 2011;6(9): e24605.

Liu X, Ji Q, Ye N, Sui H, Zhou L, Zhu H, et al. Berberine inhibits invasion and metastasis of colorectal cancer cells via COX-2/PGE2 mediated JAK2/STAT3 signaling pathway. PloS one. 2015;10(5): e0123478.

Kannan K, Holcombe RF, Jain SK, Alvarez-Hernandez X, Chervenak R, Wolf RE, et al. Evidence for the induction of apoptosis by endosulfan in a human T-cell leukemic line. Mol Cell Biochem. 2000;205(1):53-66.

Hammam OA, Aziz AA, Roshdy MS, Hadi AMA. Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. Medscape J Med. 2008;10(3):60.

Jang TJ, Lee KS. The Expression of Cyclooxygenase-2 and Surviving in Urinary Bladder Transitional Cell Carcinoma. Korean J Pathol. 2009;43(3):206-11.

Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, et al. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther. 2010;9(5):1371-7.

Daugherty SE, Pfeiffer RM, Sigurdson AJ, Hayes RB, Leitzmann M, Schatzkin A, et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol. 2011;173(7):721-30.

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs—part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106-19.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population?based to a more personalized approach to cancer staging. Cancer J Clin. 2017;67(2):93-9.

Al-Maghrabi B, Gomaa W, Abdelwahed M, Al-Maghrabi J. Increased COX-2 Immunostaining in Urothelial carcinoma of the urinary bladder is associated with invasiveness and poor prognosis. Anal Cell Pathol. 2019;2019.

Ke H-L, Tu H-P, Lin H-H, Chai C-Y, Chang L-L, Li W-M, et al. Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer. Anticancer Res. 2012;32(9):4111-6.

Shirahama T, Arima Ji, Akiba S, Sakakura C. Relation between cyclooxygenase?2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer. 2001;92(1):188-93.

Xu X-C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-cancer Drugs. 2002;13(2):127-37.

Kim YB, Kim GE, Cho NH, Pyo HR, Shim SJ, Chang SK, et al. Overexpression of cyclooxygenase?2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. CANCER. 2002;95(3):531-9.

Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res. 2000;6(6):2424-30.

Wülfing C, Eltze E, von Struensee D, Wülfing P, Hertle L, Piechota H. Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol. 2004;45(1):46-52.

Agrawal U, Kumari N, Vasudeva P, Mohanty NK, Saxena S. Overexpression of COX2 indicates poor survival in urothelial bladder cancer. Ann Diagn Pathol. 2018; 34:50-5.

Wadhwa P, Goswami AK, Joshi K, Sharma SK. Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. International urology and nephrology. 2005; 37:47-53.

Tabriz HM, Olfati G, Ahmadi SA, Yusefnia S. Cyclooxygenase-2 expression in urinary bladder transitional cell carcinoma and its association with clinicopathological characteristics. Asian Pac J Cancer Prev. 2013;14(8):4539-43.

El-Anwar NM, Orieby R, El-Shorbagy SH, El-Enain AMA, Mina SN. Immunohistochemical study of cancer stem cell markers ‘OCT4’and ‘CD44’in correlation with COX2 in urinary bladder carcinoma. Egypt J Pathol. 2016;36(2):139-48.

Badary D, El Refaiy A, Sotohy T, Nassar M, Hafez M, Reda A. Comparative Immunohistochemical Study of Expression of FGFR3, HER2, COX2 in Transitional Cell Carcinoma vs. the Adjacent Urothelial Precancerous Changes. Ann Clin Pathol Res. 2018; 1(1):1003.